| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Schmidt K | |
| Neumann T | |||
| Junker HD | |||
| Sekul R | |||
| P433 | issue | 16 | |
| P304 | page(s) | 1630-1642 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Current Topics in Medicinal Chemistry | Q2734725 |
| P1476 | title | SPR-based fragment screening: advantages and applications | |
| P478 | volume | 7 |
| Q35014380 | A surface plasmon resonance approach to monitor toxin interactions with an isolated voltage-gated sodium channel paddle motif. |
| Q37257062 | Adenylating enzymes in Mycobacterium tuberculosis as drug targets |
| Q34616682 | Advances in fragment-based drug discovery platforms |
| Q34349935 | Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads |
| Q36102317 | Biophysics in drug discovery: impact, challenges and opportunities. |
| Q33453099 | Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands |
| Q38910944 | Compound Design by Fragment-Linking |
| Q34127928 | Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge |
| Q28543133 | Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design |
| Q33908733 | Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. |
| Q41897701 | Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction |
| Q30427848 | Development of phase detection schemes based on surface plasmon resonance using interferometry |
| Q38762947 | Developments in SPR Fragment Screening. |
| Q27646546 | Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography † |
| Q42954139 | Discovery of a Novel Hsp90 Inhibitor by Fragment Linking |
| Q37579402 | Dynamic template-assisted strategies in fragment-based drug discovery. |
| Q34049517 | Emerging role of surface plasmon resonance in fragment-based drug discovery. |
| Q35009555 | Evolutions in fragment-based drug design: the deconstruction-reconstruction approach |
| Q37995087 | Fragment informatics and computational fragment-based drug design: an overview and update |
| Q26826945 | Fragment screening and HIV therapeutics |
| Q35181877 | Fragment screening by surface plasmon resonance |
| Q33836468 | Fragment screening of infectious disease targets in a structural genomics environment |
| Q33730346 | Fragment-Based Drug Design |
| Q42882505 | Fragment-Based Screening by Biochemical Assays: Systematic Feasibility Studies with Trypsin and MMP12 |
| Q27660547 | Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibition |
| Q27663569 | Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors |
| Q42943017 | GPC Spin Column HPLC–ESI-MS Methods for Screening Drugs Noncovalently Bound to Proteins |
| Q104495300 | Grating-coupled interferometry reveals binding kinetics and affinities of Ni ions to genetically engineered protein layers |
| Q33621193 | HTS and hit finding in academia--from chemical genomics to drug discovery |
| Q35181268 | Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery |
| Q27683710 | Hitting the target: fragment screening with acoustic in situ co-crystallization of proteins plus fragment libraries on pin-mounted data-collection micromeshes |
| Q52716065 | Identification of Alprenolol Hydrochloride as an Anti-prion Compound Using Surface Plasmon Resonance Imaging. |
| Q28597211 | Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies |
| Q38877288 | Identification of an anti-TB compound targeting the tyrosyl-tRNA synthetase |
| Q34334146 | In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance |
| Q91645785 | Inhibitors of Brassinosteroid Biosynthesis and Signal Transduction |
| Q51052744 | Label-Free Sensing on Microarrays. |
| Q57230716 | MS methods to study macromolecule-ligand interaction: Applications in drug discovery |
| Q61641826 | Materials and methods of signal enhancement for spectroscopic whole blood analysis: Novel research overview |
| Q30394538 | Measurement of Protein−Ligand Binding Constants from Reaction-Diffusion Concentration Profiles |
| Q48166476 | NMR-Fragment Based Virtual Screening: A Brief Overview |
| Q28297997 | Network pharmacology: the next paradigm in drug discovery |
| Q91329856 | Novel Small Molecules Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein Protect Against Diverse α-Synuclein Mediated Dysfunctions |
| Q35741775 | One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment Hit Lists |
| Q26738768 | Process of Fragment-Based Lead Discovery-A Perspective from NMR |
| Q37940197 | Progress in the discovery of small-molecule inhibitors of bromodomain--histone interactions |
| Q42314613 | Protein-Templated Formation of an Inhibitor of the Blood Coagulation Factor Xa through a Background-Free Amidation Reaction |
| Q36758601 | Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces |
| Q35231270 | Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders |
| Q38662300 | Spatially addressable chemoselective C-terminal ligation of an intein fusion protein from a complex mixture to a hydrazine-terminated surface |
| Q35738960 | State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors |
| Q38307244 | Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis |
| Q28084507 | Surface plasmon resonance: a versatile technique for biosensor applications |
| Q37303853 | Targeting and tinkering with interaction networks |
| Q33852396 | Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. |
| Q27489856 | The Role of Medical Structural Genomics in Discovering New Drugs for Infectious Diseases |
| Q33622886 | The antituberculosis antibiotic capreomycin inhibits protein synthesis by disrupting interaction between ribosomal proteins L12 and L10. |
| Q33469695 | The multiple roles of computational chemistry in fragment-based drug design |
| Q89476923 | Theory and applications of differential scanning fluorimetry in early-stage drug discovery |
| Q38392123 | Use of Microarrays as a High-Throughput Platform for Label-Free Biosensing |
| Q90115502 | Zika virus proteins at an atomic scale: how does structural biology help us to understand and develop vaccines and drugs against Zika virus infection? |
Search more.